Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3

Interventions

Cyclophosphamide 548pembrolizumab 384Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Has results × 16-fluoroestradiol × Clear all
NCT04692103 2026-01-22

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

University of Washington

Phase 2 Active not recruiting
2 enrolled 8 charts
Breast

Breast Neoplasms

NCT03703492 2025-02-12

Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS

University of Wisconsin, Madison

Phase 2 Completed
12 enrolled 9 charts
Breast

Breast Neoplasms

NCT02149173 2021-06-30

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

University of Washington

Phase NA Terminated
29 enrolled 9 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡